May 29, 2009 / 8:55 AM / 10 years ago

UPDATE 1-Lipoxen says Baxter buys 4.8 pct stake in co

* Baxter pays $1 mln for 7.3 mln shares

* Lipoxen raises 2.9 mln stg via discounted share issue

* Says funds to be used for R&D, working capital

* Lipoxen shares rise as much as 11 pct (Adds details)

May 29 (Reuters) - British drug developer Lipoxen Plc LIPX.L said it raised 2.9 million pounds ($4.6 million) in a discounted share issue, in which Baxter International Inc (BAX.N) bought a 4.8 percent stake in the company.

The company, which develops biologic drugs and vaccines, said U.S. healthcare firm Baxter bought about 7.3 million shares for $1 million.

Institutional investors, some directors and senior management also acquired shares under the programme offering 34.2 million new shares, or about 22.2 percent of its enlarged share capital, Lipoxen said in a statement.

The shares were sold at 8.5 pence per share, a 39 percent discount to the stock’s mid-market closing price on Wednesday on the London Stock Exchange, the company said. Lipoxen plans to use the proceeds from the share sale for pre-clinical research and development, feasibility studies and working capital purposes among other things, it said.

Lipoxen shares were up 3.6 percent at 14.25 pence at 0850 GMT. They earlier touched a trading high of 15.25 pence. ($1=.6263 Pound) (Reporting by Kumar Alagappan in Bangalore; Editing by Gopakumar Warrier)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below